高级医学编辑 药学专业
摘要:Isavuconazonium Sulfate: A Powerful Antifungal Agent Isavuconazonium Sulfate, also known as ISV, is a new antifungal medication that fights off a wide range of fungal infections. It is an intravenous
Isavuconazonium Sulfate: A Powerful Antifungal Agent
Isavuconazonium Sulfate, also known as ISV, is a new antifungal medication that fights off a wide range of fungal infections. It is an intravenous medication available in a capsule form, approved by the Food and Drug Administration (FDA) in March 2015 for use in patients with invasive aspergillosis and mucormycosis.
As a prodrug of Isavuconazole, ISV is rapidly converted into its active form when taken orally with food or as an intravenous infusion. This medication is used to treat infections caused by fungi such as Aspergillus spp., Fusarium spp., Scedosporium spp., and many others. It is also used for the prevention of fungal infections in high-risk patients.
ISV works by inhibiting the enzyme 14伪-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. This medication interferes in the growth and multiplication of the fungus, ultimately killing it.
Clinical trials have shown that ISV is effective and well-tolerated in treating both invasive aspergillosis and mucormycosis. In a study of 37 patients with invasive aspergillosis, 64.9% of the patients achieved a complete or partial response. Another study of 37 patients with mucormycosis showed that 42.1% of the patients achieved a complete or partial response.
ISV is rapidly absorbed and reaches therapeutic concentrations within days of administration, ensuring timely treatment of fungal infections. It is also excreted slowly, providing benefits for the prevention of fungal infections in high-risk patients.
ISV is generally well-tolerated, with the most common side effects being nausea, diarrhea, and headache. It has also shown no significant interactions with other common medications.
In conclusion, Isavuconazonium Sulfate is a potent antifungal agent that offers a new treatment option for patients suffering from invasive aspergillosis and mucormycosis. Its efficacy, tolerability, and favorable pharmacokinetic profile make it a promising treatment option, offering hope for those facing life-threatening fungal infections.
主要包括由敏感真菌引起的多种皮肤浅表感染
美国Medicis
适用于治疗由炭疽杆菌引起的吸入性炭疽病
美国Human Genorne Sciences
可治疗由毛癣菌、犬小孢子菌和絮状表皮癣菌等引起的皮肤、头发和甲的感染
美国诺华制药公司
SER-109 fecal microbiota spores, live-brpk Vowst
适用于预防18岁及以上患者在接受复发性艰难梭菌感染(CDI)的抗菌治疗后艰难梭菌感染的复发
美国Seres Therapeutics
卡泊芬净 Caspofungin Acetate Cancidas
适用于对其他治疗无效或不能耐受的侵袭性曲霉菌病
日本Astellas制药
用于治疗严重难治性感染性疾病。
日本第一三共
高级医学编辑 药学专业
正规网站
正规网站 信息服务信息查询
信息查询 真实有效隐私保护
隐私保护 安全放心免费咨询
免费信息咨询服务平台授权
数据服务 全球收录专业客服
专业客服在线服务特别声明:本站内容仅供参考,不作为诊断及医疗依据。本网站不销售任何药品,只做药品信息资讯展示!
不良信息举报邮箱:zsex@foxmail.com 版权所有 Copyright©2023 www.yzgmall.com All rights reserved
互联网药品信息服务资格证书编号:(粤)-非经营性-2021-0182
| 粤ICP备2021070247号
| 药直供手机端
|
网站地图